U.S. markets open in 4 hours 29 minutes
  • S&P Futures

    4,554.75
    +10.25 (+0.23%)
     
  • Dow Futures

    35,436.00
    +47.00 (+0.13%)
     
  • Nasdaq Futures

    15,657.50
    +70.25 (+0.45%)
     
  • Russell 2000 Futures

    2,255.00
    +5.50 (+0.24%)
     
  • Crude Oil

    82.20
    -0.46 (-0.56%)
     
  • Gold

    1,803.30
    +4.50 (+0.25%)
     
  • Silver

    24.17
    -0.03 (-0.11%)
     
  • EUR/USD

    1.1593
    -0.0013 (-0.12%)
     
  • 10-Yr Bond

    1.5290
    0.0000 (0.00%)
     
  • Vix

    16.87
    +0.89 (+5.57%)
     
  • GBP/USD

    1.3750
    +0.0008 (+0.06%)
     
  • USD/JPY

    113.6190
    -0.1910 (-0.17%)
     
  • BTC-USD

    60,594.32
    +1,335.02 (+2.25%)
     
  • CMC Crypto 200

    1,462.42
    -11.91 (-0.81%)
     
  • FTSE 100

    7,238.30
    -14.97 (-0.21%)
     
  • Nikkei 225

    28,820.09
    -278.15 (-0.96%)
     

ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BURLINGAME, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 at 10:50 am ET.

A live webcast of the presentation is available here and can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 30 days following the presentation date.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology’s website at www.alxoncology.com.

CONTACT: Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext. 113 peter@alxoncology.com Argot Partners (212)-600-1902 alxoncology@argotpartners.com Media Contact: Karen Sharma MacDougall (781) 235-3060 alx@macbiocom.com